19 completed. 19 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
Follow Dengue Hemorrhagic Fever: new trials by email Literature Review of Dengue Hemorrhagic Fever trials Research Report on Dengue Hemorrhagic Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 133 | 2019-11-06 | 2024-07-19 |
| Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Ivermectin - Dengue Hemorrhagic Fever | Phase 2 | Completed | Mahidol University | 24 | 2018-09-04 | 2021-02-24 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 118 | 2016-07-01 | 2022-03-24 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age CYD Dengue Vaccine, Placebo (Sodium chloride 0.9%) - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1050 | 2016-05-02 | 2022-03-24 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 251 | 2016-04-14 | 2022-03-24 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine CYD Dengue Vaccine, Japanese Encephalitis Vaccine - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2013-11-05 | 2022-03-24 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus, Placebo: NaCl 0.9% solution - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 189 | 2012-03-01 | 2022-04-05 |
| Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 390 | 2011-12-06 | 2022-03-24 |
| Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus, NaCl 0.9%, Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed - Dengue, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 150 | 2010-08-01 | 2022-03-21 |
| A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus, OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines, Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi | 210 | 2010-01-01 | 2013-02-06 |
| Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America CYD Dengue Vaccine, Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis - Dengue, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 600 | 2009-10-01 | 2022-03-24 |
| Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore CYD Dengue vaccine, NaCl + influenza virus or hepatitis A vaccine - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1198 | 2009-04-07 | 2022-03-21 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects CYD dengue vaccine serotypes (1, 2, 3, 4)., Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 180 | 2009-03-01 | 2022-04-05 |
| Efficacy and Safety of Dengue Vaccine in Healthy Children CYD Dengue Vaccine, Inactivated rabies virus vaccine, Placebo - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 4002 | 2009-02-01 | 2022-04-05 |
| Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-09-26 | 2022-04-05 |
| Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero), Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero), Tetravalent CYD-1,2,3,4 Dengue (Vero) - Dengue Virus, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 154 | 2008-08-01 | 2015-03-03 |
| Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi | 260 | 2008-04-17 | 2019-06-11 |
| A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Placebo, T-DEN-Post-Transfection F17, T-DEN-Post-Transfection F19 - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 636 | 2007-07-01 | 2017-07-02 |
| Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Chimeric dengue serotype (1, 2, 3, 4) - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi | 35 | 2006-08-01 | 2018-02-27 |
Severe Dengue (19) · Dengue (18) · Acquired Immunodeficiency Syndrome (1) · Virus Diseases (1) · Yellow Fever (1)
Arbovirus Infections (19) · Flaviviridae Infections (19) · Flavivirus Infections (19) · Hemorrhagic Fevers, Viral (19) · Infections (19) · Mosquito-Borne Diseases (19) · RNA Virus Infections (19) · Vector Borne Diseases (19) · Virus Diseases (18) · Blood-Borne Infections (1) · Communicable Diseases (1) · Dengue (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1)
Sodium Chloride (5) · ChimeriVax (2) · Dengue Vaccines (2) · Dosage Forms (2) · adacel (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Hepatitis A Vaccines (1) · Ivermectin (1) · Japanese Encephalitis Vaccines (1) · Measles-Mumps-Rubella Vaccine (1) · Pneumococcal Vaccines (1) · Solutions (1) · Tetanus Toxoid (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1)
Sanofi Pasteur, a Sanofi Company (14) · Sanofi (3) · Mahidol University (1) · U.S. Army Medical Research and Development Command (1)
Brazil (3) · Colombia (3) · Mexico (3) · Puerto Rico (3) · United States (3) · Honduras (2) · Philippines (2) · Singapore (2) · Thailand (2) · Australia (1) · India (1) · Peru (1) · Vietnam (1)
Alberto Santiago-Cornier, MD (1) · Anna Quintero, MD (1) · Clemente Diaz-Perez, MD (1) · Domingo Chardon-Feliciano, MD (1) · Evelyn Matta-Fontanet, MD (1) · Ines O. Esquilin-Rivera, MD (1) · Javier Morales-Ramirez, MD (1) · Jorge Bertran-Pasarell, MD (1) · Jose Rodriguez-Santana, MD (1) · Jose Tavarez-Valle, MD (1) · Luis Rodriguez-Carrasquillo, MD (1) · Miguel Sosa-Padilla, MD (1)
PMID 32932330, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23540847, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24189367, PMID 25483647, PMID 26175027, PMID 26214039, PMID 26291554, PMID 27102820, PMID 29897841, PMID 30241510, PMID 30986790, PMID 31464558, PMID 33212067, PMID 33626291, PMID 33822015, PMID 35364022, PMID 39308445, PMID 39356094, PMID 41213642, PMID 42773329
2014 (4)